Post-stroke Neural Plasticity With Atomoxetine

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This proposal evaluates the safety and effectiveness of a noradrenergic drug named atomoxetine combined with motor training to enhance cortical plasticity and improve hand function after stroke.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lumy Sawaki; University of Kentucky
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• Chronic stroke patients

• Single stroke

• Chronic (more than 6 months after from stroke)

• At least 21 years old, but there is no upper age range for this project.

• Participants NOT able to extend the affected metacarpophalangeal joints at least 10° and the wrist 20°.

Exclusion Criteria:

• History of head injury with loss of consciousness

• History of severe alcohol or drug abuse

• History of psychiatric illness

• Unstable cardiac dysrhythmia

• High blood pressure (systolic pressure >160 mm Hg and/or diastolic pressure >100 mm Hg)

• History of myocardial infarction or unstable angina

• Pregnancy

• Glaucoma, history of hypersensitivity or idiosyncrasy to sympathomimetic drugs.

• Subjects using drugs suspected of interfering with plasticity, such as MAOI, alpha-adrenergic antagonists, benzodiazepines, muscarinic receptor antagonists, dopaminergic antagonists, or other neuroleptics within 3 months of recruitment.